Quotient Clinical has brought innovation to the drug development process through its unique Translational Pharmaceutics® platform, which integrates formulation development, real-time GMP manufacturing and clinical testing. This approach has been proven to accelerate timelines and reduce associated costs, driving overall improvements in R&D productivity. With over 280 employees, the company serves an international customer base – including top tier pharmaceutical and biotech organisations – from its UK headquarters, with over 75% of its customers in the USA or mainland Europe.
Mark Egerton, Chief Executive Officer of Quotient Clinical, commented: “We are delighted to be partnering with GHO Capital for the next phase of our growth. In the past few years, we have proven the benefits of Translational Pharmaceutics, and its adoption by an ever increasing number of customers continues to drive our business growth. Partnering with GHO Capital, we will now work to expand our differentiated service portfolio and extend our operational footprint internationally.”
Mike Mortimer, Executive Partner and Founder at GHO Capital, added: “Outsourced services and contract development and manufacturing is a space that GHO Capital knows extremely well. Quotient Clinical has a highly attractive business model which can be scaled and expanded – particularly across Europe and the USA – making this an excellent investment opportunity for our fund. We look forward to working with the management team to further support the company’s international expansion.”
Alan Payne, Partner of Bridgepoint Development Capital, exiting shareholder from Quotient Clinical, said: “Our investment in Quotient was a significant opportunity for the management team to help it grow the company’s capability, grow its market share, as well as refine its international strategy and business model. It has done all of these and more, increasing its market penetration – especially in the large pharma sector – and creating an attractive, high growth platform.”